Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Takeda Pharma Reports Top-line Results From GEMINI II Pivotal Phase 3 Trial

5/11/2012 2:41 AM ET

Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFa antagonists. Crohn's disease is an inflammatory bowel disease.

The company noted that many of the patients included in the study had failed two or more TNFa antagonists. Patients received a year of vedolizumab (MLN0002) or placebo treatment, starting with six weeks of induction therapy. In both phases of the trial, induction and maintenance, vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission versus placebo. Besides, vedolizumab provided a numerically higher rate of improved response, the other primary end point in the induction phase, although not statistically significant.

According to Takeda Pharma, the most common adverse events reported in both the vedolizumab arm and the placebo arm were Crohn's disease, arthralgia(joint pain), pyrexia(fever), nasopharyngitis(upper respiratory inflammation), headache, nausea, and abdominal pain.

Register
To receive FREE breaking news email alerts for Takeda Pharmaceutical Company Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
There was a mixed performance on Wall Street on Friday. Shares suffered an early decline, as investors continued to express worries about the Federal Reserve. A recovery through the rest of the day allowed the Dow to edge into positive territory by the close. The Nasdaq and S&P 500 posted fractional losses. Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session. After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.